Вавилова Ирина Викторовна

This study compares three TBEV vaccine candidates—mRNA-LNP, recombinant adenovirus, and YFV chimera—and finds the mRNA-LNP vaccine has higher immunogenicity and protective efficacy in mice.

The paper assesses seroprevalence and cross-reactivity of neutralizing antibodies to six adenovirus types and suggests Ad1 or Ad2 as potential vaccine vector candidates.